Clinical trials: Virus
Acquired Immunodeficiency Syndrome, HIV Infections
Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
This study will evaluate the noninferiority of Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF)) single-tablet regimen (STR) relative to regimens consisting of a nonnucleoside reverse…
- Trial name
- NCT01495702
- Testing
- NNRTI, FTC/TDF, Stribild
- Where
- 80 sites in United States, Australia and 10 more
- Volunteers
- 439 people
- Sponsor
- Gilead Sciences
Mobile Phone Use, Hiv
Mobile HIV Prevention App for Black Women
Black women have a significantly higher risk of acquiring HIV compared to their non-Black counterparts. The purpose of this study is to refine and test a mobile HIV Prevention and Reproductive Health app developed specifically…
- Conditions
- Mobile Phone Use, Hiv, Stigma, Social
- Trial name
- In-the-kNOW (NCT05080972)
- Testing
- in-the-kNOW mobile app, Control
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Emory University
HIV-1 Infected Adults With Chronic HIV-1 Infection
Enhancement by Poly-ICLC During HIV-1 Infection
This study involves researching new approaches to treating HIV infection. Currently, HIV infection is treated with combinations of drugs called antiretrovirals.
- Trial name
- Poly-ICLC (NCT02071095)
- Testing
- Arm A: Poly-ICLC, Arm B: Normal Saline
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Nina Bhardwaj
HIV Infections
Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
The purpose of this study is to determine the safety and efficacy of a VRC DNA/rAd5 vaccine regimen in healthy, circumcised men and male-to-female (MTF) transgender persons who have sex with men.
- Trial name
- NCT00865566
- Testing
- DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine
- Where
- 22 sites in United States
- Volunteers
- 2,504 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
B-cell Immunity to Influenza (SLVP017)- Year 5, 2013
In this exploratory study, investigators will be looking at immune response differences between age groups and between the two different vaccines given to identical twins and vaccine-naive young adults.
- Trial name
- NCT03020537
- Testing
- Fluzone
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Stanford University
Herpes Zoster, Fibrosis
Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™
Study Design: Double-blinded, placebo controlled study of the efficacy of Zostavax in cirrhosis. Subjects will receive either Zostavax or placebo and will be followed for four months.
- Trial name
- NCT02958345
- Testing
- Zostavax
- Volunteers
- 28 people
- Sponsor
- Tulane University
Acute Respiratory Distress Syndrome, COVID-19
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
The purpose of this study was to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.
- Trial name
- NCT04537806
- Testing
- Brexanolone
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sage Therapeutics
HIV Infections
Helping HIV Infected Patients in South Africa Adhere to Drug Regimens
Three or more anti-HIV drugs are taken in combination as part of a treatment regimen. These drug regimens must be closely followed in order to be successful.
- Trial name
- NCT00076804
- Testing
- Directly Observed Therapy
- Where
- South Africa
- Volunteers
- 274 people
- Sponsor
- Johns Hopkins University
Chronic Hepatitis D Infection With Hepatitis B
A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D
This is a multicenter, open-label, randomized clinical trial to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination with Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients…
- Trial name
- NCT03546621
- Testing
- Myrcludex B, Myrcludex-B, Tenofovir
- Where
- 15 sites in Germany, Russia
- Volunteers
- 120 people
- Sponsor
- Hepatera Ltd.
Respiratory Syncytial Virus (RSV)
A Study to Evaluate EDP 938 Regimens in Children With RSV
A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.
- Trial name
- RSVPEDs (NCT04816721)
- Testing
- EDP-938
- Where
- 78 sites in United States, Argentina and 13 more
- Volunteers
- 99 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.
This study will evaluate the efficacy and safety of PEGASYS (peginterferon alfa-2a) in patients with HBeAg positive chronic hepatitis B.
- Trial name
- NCT01519921
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 7 sites in South Korea
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
Hiv
Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program
The Ryan White HIV/AIDS Program (RWHAP) for low-income people with HIV (PWH) is a key resource for reducing HIV health disparities and scaling up evidence-based interventions.
- Trial name
- D2S (NCT05140421)
- Testing
- Data to Suppression (D2S), Usual practice
- Where
- 27 sites in United States
- Volunteers
- 1,494 people
- Sponsor
- City University of New York
Dengue
A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children
One year follow-up on immunogenicity and safety of a booster dose of DEN vaccine administered approx. 1 year following the second dose
- Trial name
- NCT01843621
- Testing
- DEN vaccine F17
- Where
- Thailand
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
High Triglyceride Level, HIV Infection
The Impact of Omega Three Fatty Acids on Vascular Function in HIV
The study seeks to determine if the use of omega three fatty acids in individuals infected with HIV and with high triglycerides leads to improved triglyceride levels, better blood vessel function and decrease in the amount of…
- Trial name
- HOST (NCT01041521)
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Tufts University
COVID-19, SARS CoV 2 Infection
Evaluation of Point-of-Care (EPOC) for COVID-19
EPOC is designed to examine the feasibility of conducting two point-of-care (POC) tests the LumiraDx SARS-CoV-2 Antibody Test and the RightSign COVID-19 IgG/IgM Rapid Test for SARS-CoV-2 antibodies and compare the reproducibility…
- Trial name
- (EPOC) (NCT05227404)
- Testing
- LumiraDX, RightSign, Case Control
- Where
- United States
- Volunteers
- 330 people
- Sponsor
- University of Minnesota
Hepatitis C
A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)
This was a 3-part study comparing the pharmacokinetics after administration of vaniprevir (MK-7009) for participants with mild, moderate or severe hepatic insufficiency with healthy matched control participants.
- Trial name
- NCT01010906
- Testing
- Vaniprevir 300 mg, Vaniprevir 200 mg
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Labialis
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days in between.
- Trial name
- NCT00306293
- Testing
- valacyclovir
- Where
- 18 sites in United States
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
HIV Infections
Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut
The "PLUS" study is a pilot study to measure the effect of therapy intensification (with raltegravir and optional second agent) on HIV levels in the gut and blood in patients on antiretroviral therapy (ART) with viral load < 50…
- Trial name
- PLUS (NCT00884793)
- Testing
- raltegravir, Study NNRTI, Study PI
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of California, San Francisco
Hiv, Fatigue
High-Intensity Exercise to Attenuate Limitations and Train Habits in Older Adults With HIV
This is a multi-site, randomized, single-blind (researchers), active treatment concurrent control trial with individuals aged 50-80 living with HIV who experience fatigue and live a sedentary lifestyle.
- Conditions
- Hiv, Fatigue, Mobility Limitation
- Trial name
- HEALTH (NCT04550676)
- Testing
- HIIT (intervention), CME (active control), Coaching
- Where
- 3 sites in United States
- Volunteers
- 118 people
- Sponsor
- University of Colorado, Denver
HIV Infections
A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.
The primary objective is to establish the pharmacokinetic (PK) profile at steady state of nevirapine XR in HIV infected children from >=3 to <18 years of age.
- Trial name
- NCT00905489
- Testing
- Nevirapine Immediate Release (IR), Nevirapine Extended Release (XR)
- Where
- 10 sites in United States, Botswana and 2 more
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.